Dhanasekaran Sivakumaran

Dr. Dhanasekaran Sivakumaran

University of Bergen, Bergen, Norway

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Immunological Methods
Verified
Journal Article
Closed access
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
TDT Mark Doherty
T Mark Doherty
JKJohn Kenneth
John Kenneth
TGTB Trials Study Group
TB Trials Study Group

1 January 2011 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
GGG. Geojith
G. Geojith
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
SCSalesh Chandran
Salesh Chandran
JKJohn Kenneth
John Kenneth

16 May 2013 in Genes & Immunity
Verified
Journal Article
Open access
PDF file
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
SJS Jenum
S Jenum
RSR Stavrum
R Stavrum
CRC Ritz
C Ritz
DFDaniel Faurholt-Jepsen
Daniel Faurholt-Jepsen
RWR Walker
R Walker
Pediatric tuberculosis (TB) often goes undiagnosed because of the lack of reliable diagnostic methods. With the aim of assessing biomarker(s) that can aid in the diagnosis of TB infection and disease, we investigated 746 Indian children with suspected TB. Whole-blood mRNA from 210 children was examined by dual-color Reverse-Transcriptase Multiple Ligation-dependent Probe-Amplification for the expression of 45 genes and a Bio-Plex assay for the expression of cytokines/chemokines in QuantiFERON supernatants. The study shows that transcription of SEC14L1, GUSB, BPI, CCR7 and TGFβ-1 (all P0.05) was downregulated in TB disease compared with uninfected controls, while transcription of RAB33A was downregulated in TB disease compared with both latent TB (P<0.05) and controls (P<0.01). The transcription of CD4, TGFβ-1 (P<0.01) and the expression of IL-2 (P<0.01) and IL-13 (P<0.05) was upregulated in latent TB compared with that in controls. Using the Least Absolute Shrinkage and Selection Operator (lasso) model, RAB33A alone discriminated between TB disease and latent TB (area under the curve (AUC) 77.5%), whereas a combination of RAB33A, CXCL10, SEC14L1, FOXP3 and TNFRSF1A was effective in discriminating between TB disease and controls (AUC 91.7%). A combination of 11 biomarkers predicted latent TB with moderate discriminatory power (AUC 72.2%). In conclusion, RAB33A is a potential biomarker for TB disease, whereas CD4, TGFβ-1 and IL-2, IL-13 may identify latent TB in children.

4 January 2016 in Scientific Reports
Verified
Journal Article
Open access
SJSynne Jenum
Synne Jenum
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
RLRakesh Lodha
Rakesh Lodha
AMAparna Mukherjee
Aparna Mukherjee
DSDeepak K. Saini
Deepak K. Saini
HGHarleen M. S. Grewal
Harleen M. S. Grewal
The World Health Organization (WHO) calls for an accurate, rapid and simple point-of-care (POC) test for the diagnosis of pediatric tuberculosis (TB) in order to make progress “Towards Zero Deaths”. Whereas the sensitivity of a POC test based on detection of Mycobacterium tuberculosis (MTB) is likely to have poor sensitivity (70–80% of children have culture-negative disease), host biomarkers reflecting the on-going pathological processes across the spectrum of MTB infection and disease may hold greater promise for this purpose. We analyzed transcriptional immune biomarkers direct ex-vivo and translational biomarkers in MTB-antigen stimulated whole blood in 88 Indian children with intra-thoracic TB aged 6 months to 15 years and 39 asymptomatic siblings. We identified 12 biomarkers consistently associated with either clinical groups “upstream” towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1 and TIMP2) or “downstream” towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB. A biomarker signature consisting of BPI, CD3E, CD14, FPR1, IL4, TGFBR2, TIMP2 and TNFRSF1B separated children with TB from asymptomatic siblings (AUC of 88%).

9 July 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
SJSynne Jenum
Synne Jenum
MVMario Vaz
Mario Vaz
SSSumithra Selvam
Sumithra Selvam
TOTom H. M. Ottenhoff
Tom H. M. Ottenhoff
HGHarleen M. S. Grewal
Harleen M. S. Grewal
Tuberculosis (TB) is a global health concern. Treatment is prolonged, and patients on anti-TB therapy (ATT) often experience treatment failure for various reasons. There is an urgent need to identify signatures for early detection of failure and initiation of a treatment switch.We investigated how gene biomarkers and/or basic patient characteristics could be used to define signatures for treatment outcomes in Indian adult pulmonary-TB patients treated with standard ATT. Using blood samples at baseline, a 12-gene signature combined with information on gender, previously-diagnosed TB, severe thinness, smoking and alcohol consumption was highly predictive of treatment failure at 6 months. Likewise a 4-protein biomarker signature combined with the same patient characteristics was almost as highly predictive of treatment failure. Combining biomarkers and basic patient characteristics may be useful for predicting and hence identification of treatment failure at an early stage of TB therapy.

1 October 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
DSDhanasekaran Sivakumaran
Dhanasekaran Sivakumaran
SJSynne Jenum
Synne Jenum
RSRuth Stavrum
Ruth Stavrum
HWHarald G. Wiker
Harald G. Wiker
JKJohn Kenneth
John Kenneth
TGTB Trials Study Group
TB Trials Study Group
Non-tuberculous mycobacteria (NTM) are different from Mycobacterium tuberculosis (MTB) both in their ubiquitous environmental distribution and in their reduced capacity to cause disease. While often neglected in favour of other infectious diseases, NTM may interfere with important aspects of TB control and management, namely the efficacy of new anti-tuberculosis (TB) vaccines; the immuno-diagnostic Tuberculin skin test (TST) and QuantiFERON TB Gold In Tube assay (QFTGIT); and immune biomarkers explored for their diagnostic and/or predictive potential. Our objective was therefore to explore host immune biomarkers in children who had NTM isolated from respiratory and/or gastric specimens. The present study was nested within a prospective cohort study of BCG-vaccinated neonates in Southern India. In this setting, immune biomarkers from peripheral blood were analyzed in 210 children aged <3 years evaluated for TB using dual-colour-Reverse-Transcriptase-Multiple-Ligation-dependent-Probe-Amplification (dcRT-MLPA) and Bio-Plex assays. The children were classified based on clinical examination, chest X-rays and mycobacterial culture reports as either: 1) TB disease, 2) NTM present and 3) controls. The study shows a down-regulation of RAB33A (p<0.001) and up-regulation of TGFβ1, IL-2 and IL-6 (all p<0.05) in children with TB disease, and that RAB33A, TGFBR2 and IL-10 (all p<0.05) were differentially expressed in children with NTM present when compared to children that were culture negative for MTB and NTM (controls). Carriage of NTM may reduce the specificity of future diagnostic and predictive immune biomarkers relevant to TB management. Non-tuberculous mycobacteria (NTM) are a ubiquitous group of mycobacteria found in the environment. They are opportunistic pathogens causing human disease, especially in immunocompromised individuals. Differentiation between NTM infection and tuberculosis (TB) can be difficult. Data on incidence of NTM in TB endemic countries is limited due to resource intensive methods required for identification and a considerable workload due to other diseases. The present study was based on children investigated for TB and classified according to chest X-rays and mycobacterial culture reports. We explored host immune biomarkers which are potentially relevant to TB management, in children with confirmed NTM exposure. The findings from the present study suggest that NTM exposure modulates TB-relevant immune biomarkers in the host by eliciting some of the same immune responses as MTB infection. This is may be of importance when evaluating immunological correlates of protection in the setting of TB vaccine trials and potential TB diagnostic biomarkers.